Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.08%
2Buy18.56%
3Hold10.15%
4Sell5.79%
5Strong Sell2.83%
S&P50011.24%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Trades from $1

Zacks News

Aurinia Completes Final Patient Treatment in Dry Eye Study

Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.

Satsuma Plunges on Disappointing Data on Migraine Treatment

Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.

Urmimala Biswas headshot

3 Coronavirus-Led Threats to MedTech That May Linger

Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.

Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug

Roche (RHHBY) acquires Stratos Genomics to advance the development of its nanopore sequencer as well as releases positive data on its NMOSD Drug.

Intercept's (ICPT) Q1 Earnings and Revenues Beat Estimates

Intercept (ICPT) reports better-than-expected results for the first quarter of 2020 on solid Ocaliva sales.

Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y

Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.

Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales

Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.

Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.

AbbVie's (ABBV) Q1 Earnings and Sales Surpass Estimates

AbbVie (ABBV) beats on earnings and revenues in the first quarter of 2020. Shares up in pre-market trading.

Allergan (AGN) to Report Q1 Earnings: What's in the Cards?

On Allergan's (AGN) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

    Allergan (AGN) Earnings Expected to Grow: Should You Buy?

    Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

    AbbVie's (ABBV) Q1 top line is likely to have been impacted by biosimilar competition for Humira in international markets. However, oncology drugs may have demonstrated strong growth.

    Roche (RHHBY) Q1 Sales Grow on Solid Performance of New Drugs

    Solid sales of Roche's (RHHBY) new drugs in the first quarter more than offset the competition from biosimilars.

    Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak

    Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.

    Sweta Killa headshot

    Top-Ranked ETFs & Stocks to Buy From Bargain Industries

    Given recovering fundamentals, investors should take advantage of the beaten-down prices. For them, we have highlighted four solid ETF & stock picks each from the industries that are currently undervalued and have a solid Zacks Rank.

    Is AbbVie a Good Stock to Buy Amid Coronavirus Uncertainty?

    AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.

    Allergan (AGN) Down 5.9% Since Last Earnings Report: Can It Rebound?

    Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval

    Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.

    Kinjel Shah headshot

    Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates

    Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.

    Editas, Allergan Start Dosing in Early-Stage Eye Disease Study

    Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.

    Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates

    Editas (EDIT) misses on earnings and revenues in fourth-quarter 2019.

    Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat

    Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.

    Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS

    Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS

    Tracey Ryniec headshot

    One of Your Stock Investments is Being Acquired: Now What?

    One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.

    Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates

    Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.